Resveratrol Modulates Apoptosis- and Cell Cycle-Related Gene Expression in Ishikawa Endometrial Cancer Cells

Abstract

Background: The present study investigated the impact of resveratrol on cellular viability, apoptotic activity, proliferative capacity, and estrogen receptor/PTEN-associated signaling pathways in the ER-positive endometrial cancer cell line Ishikawa. Methods: Ishikawa cells were treated with different concentrations of resveratrol, and cell viability was assessed at 24, 48, and 72 hours using the MTT test. Based on dose-response results, sub-cytotoxic doses (15 and 30 μM) were selected for molecular studies. mRNA expression of apoptosis-related genes (BAX, BCL-2, CASP3), the proliferation marker CCND1, estrogen receptor gene ESR1, and tumor suppressor PTEN was quantified using qRT-PCR. Results: Resveratrol treatment caused a progressive, dose- and time-dependent decrease in Ishikawa cell viability. qRT-PCR analysis demonstrated upregulation of pro-apoptotic BAX and CASP3, downregulation of anti-apoptotic BCL-2 and proliferation-associated CCND1, significant suppression of ESR1, and dose-dependent elevation of PTEN expression. An increased BAX/BCL-2 ratio indicates that cellular homeostasis has shifted towards a pro-apoptotic state. Conclusion: These results indicate that resveratrol promotes pro-apoptotic transcriptional responses and reduces cell viability, potentially associated with changes in genes related to estrogen receptor signaling and PTEN pathways. The observed effects at sub-cytotoxic concentrations suggest resveratrol as a promising candidate for experimental adjunct therapy in ER-positive endometrial cancer models.

Keywords

• Endometrial cancer
• Resveratrol
• Apoptosis
• Cell Proliferation
• Estrogen Receptor

Resveratrol, Ishikawa Endometriyal Kanser Hücrelerinde Apoptoz ve Hücre Döngüsü ile İlişkili Gen Ekspresyonunu Modüle Eder

Abstract

Giriş: Bu çalışma, ER-pozitif endometriyal kanser hücre hattı Ishikawa’da resveratrolün hücre canlılığı, apoptoz, proliferasyon ve östrojen reseptörü/PTEN ile ilişkili yolaklar üzerindeki etkilerini incelemeyi amaçlamıştır. Yöntemler: Ishikawa hücrelerine farklı konsantrasyonlarda resveratrol uygulanmış ve hücre canlılığı 24, 48 ve 72 saatlerde MTT testi ile değerlendirilmiştir. Doz–yanıt sonuçlarına dayanarak moleküler analizler için sub-sitotoksik dozlar (15 ve 30 μM) seçilmiştir. Apoptoz ile ilişkili genlerin (BAX, BCL-2, CASP3), proliferasyon belirteci CCND1’in, östrojen reseptör geni ESR1’in ve tümör baskılayıcı PTEN’in mRNA ekspresyon düzeyleri qRT-PCR yöntemi kullanılarak kantitatif olarak belirlenmiştir. Bulgular: Resveratrol uygulaması Ishikawa hücre canlılığında doza ve zamana bağlı, progresif bir azalmaya yol açmıştır. qRT-PCR analizleri, pro-apoptotik BAX ve CASP3 genlerinde artış; anti-apoptotik BCL-2 ve proliferasyonla ilişkili CCND1 genlerinde azalma; ESR1 ekspresyonunda belirgin baskılanma ve PTEN ekspresyonunda doza bağlı artış olduğunu göstermiştir. Artmış BAX/BCL-2 oranı, hücresel dengenin pro-apoptotik yönde değiştiğini göstermektedir. Sonuç: Bu bulgular, resveratrolün pro-apoptotik transkripsiyonel yanıtları desteklediğini ve hücre canlılığını azalttığını; bu etkilerin östrojen reseptörü sinyallemesi ve PTEN ile ilişkili genlerde meydana gelen değişikliklerle ilişkili olabileceğini göstermektedir. Sub-sitotoksik konsantrasyonlarda gözlenen etkiler, resveratrolün ER-pozitif endometriyal kanser modellerinde deneysel adjuvan tedavi için umut verici bir aday olabileceğini düşündürmektedir.

Keywords

• Endometriyal kanser
• Resveratrol
• Apoptoz
• Hücre proliferasyonu
• Östrojen reseptörü.

References

1. 1.Anca-Stanciu MB, Manu A, Olinca MV, et al.Comprehensive review of endometrial cancer: newmolecular and FIGO classification and recenttreatment changes. J Clin Med. 2025; 14: 1385.
2. 2.Agnew HJ, Baker-Rand H, Kitson SJ, Crosbie EJ.Leading causes of death after a diagnosis ofendometrial cancer: a systematic review and meta-analysis. Obstet Gynecol Surv. 2025; 80: 701-2.
3. 3.Onstad MA, Schmandt RE, Lu KH. Addressing therole of obesity in endometrial cancer risk,prevention, and treatment. J Clin Oncol. 2016; 34:4225-30.
4. 4.Setiawan VW, Yang HP, Pike MC, et al. Type I andII endometrial cancers: have they different riskfactors? J Clin Oncol. 2013; 31: 2607-18.
5. 5.Roncolato F, Lindemann K, Willson ML, et al.PI3K/AKT/mTOR inhibitors for advanced orrecurrent endometrial cancer. Cochrane DatabaseSyst Rev. 2019; 10: CD012160.
6. 6.Hu Y, Liu P, Rosen N, Jiang X. Targeting mTORC1to promote ferroptosis and apoptosis in endometrial cancer with PI3K-Akt-mTOR pathway mutation.Ferroptosis Oxid Stress. 2025; 1: 202504.
7. 7.Vidal-Sabanés M, Bonifaci N, Navaridas R, et al.Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503. Cell DeathDis. 2025; 16: 705.
8. 8.Vogler M, Braun Y, Smith VM, et al. The BCL2family: from apoptosis mechanisms to newadvances in targeted therapy. Signal TransductTarget Ther. 2025; 10: 91.

9. 9. Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. Therole of BCL-2 family proteins in regulating apoptosisand cancer therapy. Front Oncol. 2022; 12: 985363.
10. 10.Jeffreys SA, Becker TM, Khan S, et al. Prognosticand predictive value of CCND1/cyclin D1amplification in breast cancer with a focus onpostmenopausal patients: a systematic review andmeta-analysis. Front Endocrinol (Lausanne). 2022;13: 895729.
11. 11.Salehi B, Mishra AP, Nigam M, et al. Resveratrol:a double-edged sword in health benefits.Biomedicines. 2018; 6: 91.
12. 12.Liu Y, Tong L, Luo Y, Li X, Chen G, Wang Y.Resveratrol inhibits proliferation and inducesapoptosis in ovarian cancer cells via inhibition ofglycolysis and targeting the AMPK/mTOR signalingpathway. J Cell Biochem. 2018; 119: 6162-72.
13. 13.Qin X, Luo H, Deng Y, Yao X, Zhang J, He B.Resveratrol inhibits proliferation and inducesapoptosis via the Hippo/YAP pathway in humancolon cancer cells. Biochem Biophys Res Commun.2022; 636: 197-204.
14. 14.Poschner S, Maier-Salamon A, Zehl M, et al.Resveratrol inhibits key steps of steroid metabolism in a human estrogen receptor–positive breastcancer model: impact on cellular proliferation. Front Pharmacol. 2018; 9: 742.
15. 15.Qasem RJ. The estrogenic activity of resveratrol:a comprehensive review of in vitro and in vivoevidence and the potential for endocrine disruption.Crit Rev Toxicol. 2020; 50: 439-62.
16. 16.Fukuda T, Oda K, Wada-Hiraike O, et al.Autophagy inhibition augments resveratrol-inducedapoptosis in Ishikawa endometrial cancer cells.Oncol Lett. 2016; 12: 2560-6.
17. 17.Almatroodi SA, Alsahli MA, Aljohani ASM, et al.Potential therapeutic targets of resveratrol, a plantpolyphenol, and its role in the therapy of varioustypes of cancer. Molecules. 2022; 27: 2665.
18. 18.Fu X, Wang Y, Li M, et al. Targeting of cancer celldeath mechanisms by resveratrol: a review.Apoptosis. 2021; 26: 561-73.
19. 19.Kim SE, Shin SH, Lee JY, et al. Resveratrol induces mitochondrial apoptosis and inhibits epithelial–mesenchymal transition in oral squamous cellcarcinoma cells. Nutr Cancer. 2018; 70: 125-35.
20. 20.Juan ME, Wenzel U, Daniel H, Planas JM.Resveratrol induces apoptosis through ROS-dependent mitochondrial pathway in HT-29 humancolorectal carcinoma cells. J Agric Food Chem. 2008;56: 4813-8.
21. 21.Ma X, Tian X, Huang X, Yan F, Qiao D. Resveratrol-induced mitochondrial dysfunction and apoptosisare associated with Ca²⁺ and mCICR-mediated MPTactivation in HepG2 cells. Mol Cell Biochem. 2007;302: 99-109.
22. 22.Kumar S, Eroglu E, Stokes JA, et al. Resveratrolinduces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancercells. Oncotarget. 2017; 8: 20895-908.
23. 23.Atram MA, Shivkumar VB, Gangane NM.Immunohistochemical analysis of novel biomarkerscyclin D1, p53 and Ki67 in endometrial carcinoma:clinicopathological significance and prognosticvalue. Gulf J Oncol. 2022; 38: 15-23.
24. 24.Sangwan K, Garg M, Pathak N, Bharti L.Expression of cyclin D1 in hyperplasia andcarcinoma of endometrium and its correlation withhistologic grade, tumor type, and clinicopathologicalfeatures. J Lab Physicians. 2020; 12: 165-70.
25. 25.Ge Y, Ni X, Li J, Ye M, Jin X. Roles of estrogenreceptor alpha in endometrial carcinoma (review).Oncol Lett. 2023; 26: 530.
26. 26.Nwachukwu JC, Srinivasan S, Bruno NE, et al.Resveratrol modulates the inflammatory responsevia an estrogen receptor–signal integrationnetwork. eLife. 2014; 3: e02057.
27. 27.Kobylka P, Kucinska M, Kujawski J, et al.Resveratrol analogues as selective estrogensignaling pathway modulators: structure–activityrelationship. Molecules. 2022; 27: 6973.
28. 28.Lephart ED. Phytoestrogens (resveratrol andequol) for estrogen-deficient skin —controversies/misinformation versus anti-aging invitro and clinical evidence. Int J Mol Sci. 2021; 22:11218.
29. 29.Hameed JSF, Devarajan A, MSDP, et al. PTEN-negative endometrial cancer cells protect theirgenome through enhanced DDB2 expressionassociated with augmented nucleotide excisionrepair. BMC Cancer. 2023; 23: 399.
30. 30.Philip CA, Laskov I, Beauchamp MC, et al.Inhibition of PI3K–AKT–mTOR pathway sensitizesendometrial cancer cell lines to PARP inhibitors.BMC Cancer. 2017; 17: 638.
31. 31.Kanamori Y, Kigawa J, Itamochi H, et al.Correlation between loss of PTEN expression andAkt phosphorylation in endometrial carcinoma. ClinCancer Res. 2001; 7: 892-5.